GSK: CHMP gives go-ahead for dostarlimab
(CercleFinance.com) - Late on Friday GlaxoSmithKline (GSK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a favourable opinion recommending dostarlimab in women with certain endometrial cancers, recurrent or advanced, that have progressed during or after a regimen containing platinum.
"Treatment options are limited for women with recurrent or advanced endometrial cancer and prognosis is typically poor. This positive CHMP opinion brings us one step closer to providing dostarlimab as a new treatment option to women with endometrial cancer in Europe," said Dr Axel Hoos, Senior Vice President and Head of Oncology R&D at GSK.
Copyright (c) 2021 CercleFinance.com. All rights reserved.